ABSTRACT
Introduction: For every critically ill adult receiving invasive mechanical ventilation, clinicians must select a mode of ventilation. The mode of ventilation determines whether the ventilator directly controls the tidal volume or the inspiratory pressure. Newer hybrid modes allow clinicians to set a target tidal volume, for which the ventilator controls and adjusts the inspiratory pressure. A strategy of low tidal volumes and low plateau pressure improves outcomes, but the optimal mode to achieve these targets is not known.
Methods and analysis: The Mode of Ventilation During Critical Illness (MODE) trial is a cluster-randomized, multiple-crossover pilot trial being conducted in the medical intensive care unit (ICU) at an academic center. The MODE trial compares the use of volume control, pressure control, and adaptive pressure control. The study ICU is assigned to a single ventilator mode (volume control versus pressure control versus adaptive pressure control) for continuous mandatory ventilation during each 1-month study block. The assigned mode switches every month in a randomly generated sequence. The primary outcome is ventilator-free days (VFDs) to study day 28, defined as the number of days alive and free of invasive mechanical ventilation from the final receipt of mechanical ventilation to 28 days after enrollment. Enrollment began November 1, 2022 and will end on July 31, 2023.
Ethics and dissemination: The trial was approved by the Vanderbilt University Medical Center institutional review board (IRB# 220446). Results of this study will be submitted to a peer-reviewed journal and presented at scientific conferences.
Trial registration number: The trial was registered with clinicaltrials.gov on October 3, 2022, prior to initiation of patient enrollment on November 1, 2022 (ClinicalTrials.gov identifier: NCT05563779)
Competing Interest Statement
J.D.C. reports a travel support from Fisher & Paykel Healthcare. T.W.R. reports unrelated consultant relationships with Cumberland Pharmaceuticals, Inc as Director of Medical Affairs, Cytovale, Inc, and Sanofi, Inc as a member of a DSMB.
Clinical Trial
NCT05563779
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Vanderbilt University Medical Center gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Sources of funding: K.P.S. was supported by the National Heart Lung and Blood Institute (T32HL087738). E.T.Q. was supported by the NHLBI (T32HL087738). W.H.S was supported by UL1TR002243 and 1U24TR004437. T.W.R. was supported by UL1 TR002243, UL1 RR 024975, and U24 TR 001608. M.W.S. was supported in part by the NHLBI (K23HL143053). J.D.C. was supported in part by the NHLBI (K23HL153584). The project was supported by CTSA award No. UL1 TR002243 from the National Center for Advancing Translational Sciences (NCATS). Its contents are solely the responsibility of the authors and do not necessarily represent official views of the NCATS or the NIH.
Conflicts of interest and financial disclosures: J.D.C. reports a travel support from Fisher & Paykel Healthcare. T.W.R. reports unrelated consultant relationships with Cumberland Pharmaceuticals, Inc as Director of Medical Affairs, Cytovale, Inc, and Sanofi, Inc as a member of a DSMB.
Supplemental digital content is available for this article.
Data Availability
At the time of publication of the trial described in this protocol, a de-identified version of the database will be generated and available upon reasonable request to the authors.
